Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing enterobacteriaceae

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Ng, Tat Ming ^a   Khong, Wendy X ^a   Harris, Patrick N A ^b,c,d   De, Partha P ^a   Chow, Angela ^a,e   Tambyah, Paul A ^f   Lye, David C ^a,c  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

AGED; ARTICLE; BACTEREMIA; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; MYCOSIS; PROPENSITY SCORE; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SINGAPORE; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; ENTEROBACTERIACEAE; ENZYMOLOGY; MICROBIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; FEMALE; HUMANS; MALE; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES;

EID: 84977669598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153696     Document Type: Article

References (32)

1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18: 657-686. PMID: 16223952
2. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect. 2009; 73: 345-354. doi: 10.1016/j.jhin.2009.02.021 PMID: 19596491
3. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect. 2008; 14 Suppl 1: S33-41.
4. Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother. 2007; 41: 1427-1435. PMID: 17666573
5. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32: 470-485. PMID: 15573054
6. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect. 2008; 14 Suppl 1: S144-153.
7. Sheng WH, Badal RE, Hsueh PR. Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013; 57: 2981-2988. doi: 10.1128/AAC.00971-12 PMID: 23587958
8. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005; 56: 52-59. PMID: 15917288
9. Young BE, Lye DC, Krishnan P, Chan SP, Leo YS. A prospective observational study of the prevalence and risk factors for colonization by antibiotic resistant bacteria in patients at admission to hospital in Singapore. BMC Infect Dis. 2014; 14: 298. doi: 10.1186/1471-2334-14-298 PMID: 24889720
10. Hsu LY, Tan TY, Jureen R, Koh TH, Krishnan P, Tzer-Pin Lin R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis. 2007; 13: 1944-1947. doi: 10.3201/eid1312.070299 PMID: 18258055
11. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007; 55: 254-259. PMID: 17574678
12. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteraemia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39: 31-37. PMID: 15206050
13. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011; 86: 250-259. doi: 10.4065/mcp.2010.0674 PMID: 21364117
14. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012; 54: 167-174. doi: 10. 1093/cid/cir790 PMID: 22057701
15. Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2014; 69: 871-880. doi: 10.1093/jac/ dkt450 PMID: 24265230
16. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012; 67: 2793-2803. doi: 10.1093/jac/dks301 PMID: 22915465
17. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17: 1791-1798. doi: 10.3201/eid1710.110655 PMID: 22000347
18. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010; 10: 597-602. doi: 10.1016/S1473-3099(10)70143-2 PMID: 20705517
19. Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis. 2011; 53: 49-56. doi: 10.1093/cid/cir273 PMID: 21653302
20. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infect Dis. 2011; 11: 381-393. doi: 10.1016/S1473-3099(11)70056-1 PMID: 21530894
21. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011; 53: 60-67. doi: 10.1093/cid/cir202 PMID: 21653305
22. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16: 128-140. PMID: 2841893
23. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002; 137: 791-797. PMID: 12435215
24. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006; 163: 1149-1156. PMID: 16624967
25. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004; 48: 4574-4581. PMID: 15561828
26. Chaubey VP, Pitout JD, Dalton B, Ross T, Church DL, Gregson DB, et al. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes. 2010; 3: 116. doi: 10.1186/1756-0500-3-116 PMID: 20423493
27. Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol. 2015; 36: 981-985. doi: 10.1017/ice.2015.101 PMID: 25990361
28. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteraemia. Clin Infect Dis. 2015; 60: 1319-1325. doi: 10.1093/cid/civ003 PMID: 25586681
29. Lopez-Cerero L, Picon E, Morillo C, Hernandez JR, Docobo F, Pachon J, et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamasenon-producing Escherichia coli isolates. Clin Microbiol Infect. 2010; 16: 132-136. doi: 10.1111/j.1469-0691.2009.02893.x PMID: 19614715
30. Kang CI, Park SY, Chung DR, Peck KR, Song JH. Piperacillin-tazobactam as an initial empirical therapy of bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect. 2012; 64: 533-534. doi: 10.1016/j.jinf.2012.01.008 PMID: 22274414
31. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998; 244: 379-386. PMID: 9845853
32. Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp. (the MERINO trial): study protocol for a randomised controlled trial. Trials. 2015; 16: 24. doi: 10.1186/s13063-014-0541-9 PMID: 25623485